New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
09:19 EDTFOLD, COO, TSPT, AGEN, APP, NFLX, GEVA, GNRCOn The Fly: Pre-market Movers
HIGHER: Netflix (NFLX), up 3.6% after the stock was upgraded to Buy from Neutral at Goldman... Transcept Pharmaceuticals (TSPT), up 22.6% after signing a merger agreement with Paratek Pharmaceuticals... Agenus (AGEN), up 21% after announcing that in a Phase 2 study patients with newly diagnosed glioblastoma multiforme who received Agenus’ Prophage autologous cancer vaccine added to the standard of care treatment lived nearly twice as long as expected... Galena Biopharma (GALE), up 11% after announcing the notice of allowance of a U.S. patent for NeuVax... Amicus Therapeutics (FOLD), up 11.7% following upgrades at Leerink and Janney Capital... Cooper Companies (COO), up 2.6% after agreeing to acquire Saulfon Pharmaceuticals, a European maker of soft contact lenses and solutions, in a transaction valued at approximately $1.2B. LOWER: American Apparel (APP), down 4% after former CEO Dov Charney disclosed he bought 27.35M shares on June 27... Generac (GNRC), down 3% following a downgraded to Neutral from Buy at BofA Merrill Lynch... Synageva (GEVA), down 2.7% after being initiated with a Neutral rating at Citigroup.
News For NFLX;TSPT;GNRC;APP;COO;GEVA;AGEN;FOLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 26, 2015
16:48 EDTGEVASynageva reports Q4 EPS ($1.73), consensus ($1.71)
Subscribe for More Information
16:00 EDTNFLXOptions Update; February 26, 2015
iPath S&P 500 VIX Short-Term Futures down 33c to 27.78. Option volume leaders: AAPL TSLA TWTR C ZNGA MCD RIG NFLX according to Track Data.
14:23 EDTNFLXNetflix says FCC decisions are wins for consumers
Subscribe for More Information
13:12 EDTNFLXNetflix volatility at record low, shares near record high on FCC vote
Subscribe for More Information
13:00 EDTNFLXFCC votes in favor of adopting net neutrality proposals
The Federal Communications Commission voted 3 to 2 in favor of adopting new open Internet, or "net neutrality," rules. FCC Chairman Tom Wheeler has proposed that the FCC use its Title II authority to implement and enforce open Internet protections, with "bright-line" rules to ban paid prioritization and the blocking and throttling of lawful content and services. However, Wheeler said his proposal will "modernize" Title II, insuring there will be no rate regulation, no tariffs, and no last-mile unbundling. Major Internet Service Providers, including AT&T (T), Comcast (CMCSA), and Verizon (VZ), have opposed FCC Chairman Wheeler's proposals to treat Internet service similar to a utility. Other companies that provide Internet services include Time Warner Cable (TWC), CenturyLink (CTL), DIRECTV (DTV), Cablevision (CVC) and Lumos Networks (LMOS). Netflix (NFLX) has strongly supported open Internet provisions. Cogent Communications (CCOI) and Level 3 Communications (LVLT) are facilities-based providers of Internet access and Internet Protocol communications services that are likely to be impacted by FCC rules on net neutrality.
12:55 EDTNFLXFCC Chair says open Internet proposals not a plan to control the Internet
Subscribe for More Information
09:35 EDTNFLXActive equity options trading on open
Subscribe for More Information
07:08 EDTAGENAgenus reports Q4 EPS (41c), consensus (16c)
Reports Q4 revenue $1.62M, consensus $620K. Target Milestones for 2015 include: Publication of the Phase 2 data for Prophage in newly diagnosed GBM in a peer reviewed journal. Explore options for the advancement of Prophage for newly diagnosed GBM to a Phase 3 trial. Full Phase 3 data for partner GlaxoSmithKline’s HZ/su shingles vaccine are expected to be presented at a scientific conference and submitted for publication in a peer-reviewed journal. The vaccine contains Agenus’ proprietary QS-21 Stimulon adjuvant. EMA regulatory decision on GlaxoSmithKline’s malaria vaccine candidate RTS,S, which contains Agenus’s QS-21 Stimulon adjuvant. File Investigational New Drug applications for two checkpoint modulator antibody programs as part of our global oncology alliance with Incyte.
February 25, 2015
11:47 EDTNFLXAnalysts clash on DreamWorks following Q4 miss
The shares of animated film and television show maker DreamWorks (DWA) are rising, despite the weaker than expected results reported by the company last night. Two analysts offered very different views on the company's outlook following its results. BACKGROUND: DreamWorks last night reported a fourth quarter per share loss of ($3.08), versus analysts' consensus outlook for a ($3.01) per share loss. The company's revenue also came in below expectations. Excluding $210M in pre-tax charges associated with DreamWorks' restructuring plan, its loss was (75c) per share, the company stated. BEARISH TAKE: In a note to investors today, FBR Capital analyst Barton Crockett wrote that DreamWorks' results were "ugly," as they included $155M of write-offs on films and TV shows. However, Crockett believes that the crucial factor for the company's outlook is whether it can consistently compete with the entertainment giants, including Disney (DIS), Viacom (VIA), and Time Warner (TWX). Crockett is not convinced that DreamWorks will be able to hold its own, and he believes that its 2015 results could come in below expectations. The analyst warned that the company may have difficulty meeting its 2015 consumer products revenue guidance. DreamWorks expects its consumer products revenue to double this year, but the movie-based toy space is "very competitive" in 2015, as toys based on multiple popular children's films are set to be released, Crockett stated. Moreover, after conducting checks online, Crockett reports that there does not seem to be a great deal of interest in DreamWorks' movie "Home," which is set to be released on March 27. He kept an Underperform rating on the shares and raised his price target on the stock to $14 from $12. BULLISH TAKE: DreamWorks' results were mixed, but the results are not very important, Piper Jaffray analyst James Marsh stated. The company's guidance for its TV and consumer products businesses were solid, the analyst believes. Moreover, the company "took specific and decisive action" to avert a liquidity crunch, Marsh wrote. Specifically, DreamWorks raised $185M of capital by selling its real estate in Glendale, California and then leasing it back, and increased the size of its current credit facility to $450M from $400M, Marsh reported. The moves should "largely" eliminate investors' worries about the company's liquidity position, Marsh stated. He kept a $26 price target and Overweight rating on the stock. WHAT'S NOTABLE: On DreamWorks' earnings conference call last night, the company's CEO Jeffrey Katzenberg stated that it did not obtain more than 10% of its revenue from Netflix (NFLX) last year. However, in an SEC filing earlier this morning, DreamWorks clarified that it had obtained 14.9% of its revenue from Netflix last year. PRICE ACTION: In late morning trading, DreamWorks rose 5.6% to $22.31.
11:19 EDTNFLXNetflix to premiere five new shows for kids
Netflix announced that it is adding five new animated and live-action comedy series to its selection of kids and family entertainment. These include Danger Mouse, planned for Spring 2016, Inspector Gadget in March 2015, Some Assembly Required in Summer 2015, Bottersnikes & Gumbles in Spring 2016 and SUPER 4, a new CGI animated series inspired by PLAYMOBIL, which makes its U.S. premiere in April exclusively on Netflix.
February 24, 2015
10:01 EDTNFLXNetflix teams up with Judd Apatow for 'Pee-wee's Big Holiday'
Netflix will premiere exclusively in all of its territories the new feature film, Pee-wee's Big Holiday, starring Paul Reubens as the beloved fun-loving hero of TV, stage and film, Pee-wee Herman. Judd Apatow and Reubens, who worked together to bring the project to fruition, will produce the film. Production is slated to begin in early 2015.
08:33 EDTFOLDArgos Therapeutics hires Joan Winterbottom as Chief Human Resources Officer
Argos Therapeutics (ARGS) announced that Joan Winterbottom will join the company as chief human resources officer. Winterbottom most recently served as senior vice president of human resources at Amicus Therapeutics (FOLD).
07:15 EDTNFLXNetflix may enter Russia within two years, Hollywood Reporter says
Netflix' head of communications in Europe, Joris Evers, says the company hopes to make its entrance in Russia within the next two years, The Hollywood Reporter says. Reference Link
February 23, 2015
16:33 EDTAPPAmerican Apparel announces two leadership appointments
Subscribe for More Information
08:09 EDTGEVASynageva announces FDA accepts accepts BLA filing for Kanuma
Subscribe for More Information
07:22 EDTGEVA, FOLDSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
February 19, 2015
16:01 EDTNFLXOptions Update; February 19, 2015
iPath S&P 500 VIX Short-Term Futures down 70c to 30.11. Option volume leaders: AAPL TSLA TWTR AMAT PBR KO FB AXP NFLX according to Track Data.
February 18, 2015
16:00 EDTNFLXOptions Update; February 18, 2015
Subscribe for More Information
09:37 EDTNFLXOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
07:36 EDTGEVASynageva European Patent issued for treatment of LAL deficiency
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use